Abstract
Advanced glycation end products (AGEs) in diabetic nephropathy have been extensively researched over the last decade and are now firmly established as major players in this disease. The enigma remains the search for the ideal AGE inhibition therapy, which is a great challenge in the context of the structural diversity inherent to AGE chemistry. Certainly, there is a requirement to standardize measurements of circulating and tissue levels of AGEs and to characterize the pathogenic potential of specific AGE moieties. In order to develop more effective, targeted approaches to combat diabetic nephropathy, the mechanisms of action of selective AGE inhibitors and the inter-relationships of advanced glycation with other pathogenic pathways must be addressed.
Keywords: advanced glycation end products, diabetes, diabetic nephropathy, age inhibitor, cross-link breaker, cml, pentosidine, rage
Current Pharmaceutical Design
Title: Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Volume: 10 Issue: 27
Author(s): Josephine M. Forbes, Vicki Thallas-Bonke, Mark E. Cooper and Merlin C. Thomas
Affiliation:
Keywords: advanced glycation end products, diabetes, diabetic nephropathy, age inhibitor, cross-link breaker, cml, pentosidine, rage
Abstract: Advanced glycation end products (AGEs) in diabetic nephropathy have been extensively researched over the last decade and are now firmly established as major players in this disease. The enigma remains the search for the ideal AGE inhibition therapy, which is a great challenge in the context of the structural diversity inherent to AGE chemistry. Certainly, there is a requirement to standardize measurements of circulating and tissue levels of AGEs and to characterize the pathogenic potential of specific AGE moieties. In order to develop more effective, targeted approaches to combat diabetic nephropathy, the mechanisms of action of selective AGE inhibitors and the inter-relationships of advanced glycation with other pathogenic pathways must be addressed.
Export Options
About this article
Cite this article as:
Forbes M. Josephine, Thallas-Bonke Vicki, Cooper E. Mark and Thomas C. Merlin, Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy, Current Pharmaceutical Design 2004; 10 (27) . https://dx.doi.org/10.2174/1381612043383151
DOI https://dx.doi.org/10.2174/1381612043383151 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets The Correlation Between Urinary 8-Iso-Prostaglandin F2α and Hydrogen Peroxide Toward Renal Function in T2DM Patients Consuming Sulfonylurea and Combination of Metformin-Sulfonylurea
Current Diabetes Reviews Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Human Islet Transplantation: Current Status and Future Direction
Micro and Nanosystems Effect of Rosuvastatin on Non-alcoholic Steatohepatitis in Patients with Metabolic Syndrome and Hypercholesterolaemia: A Preliminary Report
Current Vascular Pharmacology Biomarkers of Aging with Prognostic and Predictive Value in Non-Oncological Diseases
Current Medicinal Chemistry Antidiabetics Interactions with Herbs: A Compressive Review
Current Diabetes Reviews The Potential Role of Thiamine (Vitamin B1) in Diabetic Complications
Current Diabetes Reviews Therapeutic Potential of Resveratrol in Diabetic Nephropathy According to Molecular Signaling
Current Molecular Pharmacology The Glomerular Podocyte as a Target of Growth Hormone Action: Implications for the Pathogenesis of Diabetic Nephropathy
Current Diabetes Reviews Editorial (Thematic Issue: New Horizon in the Treatment of Hypertension - Role for Ca Channel Blockers - Why do Ca Channel Blockers be Focused on?)
Current Hypertension Reviews Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication
Current Drug Safety Angiotensin-Converting Enzyme Inhibitors: Mechanisms of Action and Implications In Anesthesia Practice
Current Pharmaceutical Design Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits
Cardiovascular & Hematological Disorders-Drug Targets Role of Inflammation in Diabetic Nephropathy
Current Diabetes Reviews Arterial Hypertension and Kidney Circulation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Subject Index
Current Drug Targets - Inflammation & Allergy Diagnosis of Pathogens Using DNA Microarray
Recent Patents on Biotechnology Antidiabetic Properties of Dietary Chrysin: A Cellular Mechanism Review
Mini-Reviews in Medicinal Chemistry